Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior treatment failure. We investigated the efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for 12 weeks in HCV-infected Korean adults. Methods: This Phase 3b, multicenter, open-label study included 2 cohorts. In Cohort 1, participants with HCV genotype 1 or 2 and who were treatment-naive or treatment-experienced with interferon-based treatments, received sofosbuvir–velpatasvir 400/100 mg/day. In Cohort 2, HCV genotype 1 infected individuals who previously received an NS5A inhibitor-containing regimen ≥ 4 weeks received sofosbuvir–velpatasvir–voxilaprevir 400/100/100 mg/day. Decompensated cirrhosis was an exclusion criterion. The primary endpoint was SVR12, defined as HCV RNA < 15 IU/mL 12 weeks following treatment. Results: Of 53 participants receiving sofosbuvir–velpatasvir, 52 (98.1%) achieved SVR12. The single participant who did not achieve SVR12 experienced an asymptomatic Grade 3 ASL/ALT elevation on day 15 and discontinued treatment. The event resolved without intervention. All 33 participants (100%) treated with sofosbuvir–velpatasvir–voxilaprevir achieved SVR 12. Overall, sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir were safe and well tolerated. Three participants (5.6%) in Cohort 1 and 1 participant (3.0%) in Cohort 2 had serious adverse events, but none were considered treatment-related. No deaths or grade 4 laboratory abnormalities were reported. Conclusions: Treatment with sofosbuvir–velpatasvir or sofosbuvir–velpatasvir–voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.
Abstract
Background/Aims: Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior treatment failure. We investigated the efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for 12 weeks in HCV-infected Korean adults. Methods: This Phase 3b, multicenter, open-label study included 2 cohorts. In Cohort 1, participants with HCV genotype 1 or 2 and who were treatment-naive or treatment-experienced with interferon-based treatments, received sofosbuvir–velpatasvir 400/100 mg/day. In Cohort 2, HCV genotype 1 infected individuals who previously received an NS5A inhibitor-containing regimen ≥ 4 weeks received sofosbuvir–velpatasvir–voxilaprevir 400/100/100 mg/day. Decompensated cirrhosis was an exclusion criterion. The primary endpoint was SVR12, defined as HCV RNA < 15 IU/mL 12 weeks following treatment. Results: Of 53 participants receiving sofosbuvir–velpatasvir, 52 (98.1%) achieved SVR12. The single participant who did not achieve SVR12 experienced an asymptomatic Grade 3 ASL/ALT elevation on day 15 and discontinued treatment. The event resolved without intervention. All 33 participants (100%) treated with sofosbuvir–velpatasvir–voxilaprevir achieved SVR 12. Overall, sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir were safe and well tolerated. Three participants (5.6%) in Cohort 1 and 1 participant (3.0%) in Cohort 2 had serious adverse events, but none were considered treatment-related. No deaths or grade 4 laboratory abnormalities were reported. Conclusions: Treatment with sofosbuvir–velpatasvir or sofosbuvir–velpatasvir–voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.
참고문헌 (40)
- ". Geneva: World Health Organization" (2017)[URL]
- Gamkrelidze I, "Progress towards hepatitis C virus elimination in high-income countries : an updated analysis", Liver Int, 41, pp.456~463 (2021)
- "Callto-action to advance progress towards viral hepatitis elimination:a focus on simplified approaches to HCV testing and cure" (2019)[URL]
- Mangia A, "Guidelines have a key role in driving HCV elimination by advocating for simple HCV care pathways", Adv Ther, 38, pp.1397~1403 (2021)
- Lim YS, "Current status of liver disease in Korea : hepatitis C", Korean J Hepatol, 15(Suppl 6), pp.S25~S28 (2009)
- Moore KJ, "Prevalence and sociodemographic disparities of Hepatitis C in Baby Boomers and the US adult population", J Infect Public Health, 12, pp.32~36 (2019)
- Zaltron S, "Chronic HCV infection : epidemiological and clinical relevance", BMC Infect Dis, 12(Suppl 2), pp.S2~ (2012)
- Greenaway C, "The seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries : a systematic review and meta-analysis", PLoS One, 10, pp.e0141715~ (2015)
- Thein HH, "Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection : a meta-analysis and meta-regression", Hepatology, 48, pp.418~431 (2008)
- Joon Yeul Nam, "Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study", Gut and Liver, 14(2), pp.207~217 (2020), 거트앤리버 소화기연관학회협의회
- Salive ME, "Multimorbidity in older adults", Epidemiol Rev, 35, pp.75~83 (2013)
- Park H, "Chronic hepatitis C virus(HCV)increases the risk of chronic kidney disease(CKD)while effective HCV treatment decreases the incidence of CKD", Hepatology, 67, pp.492~504 (2018)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C : final update of the series", J Hepatol, 73, pp.1170~1218 (2020)
- Ghany MG, "Hepatitis C guidance 2019 update : American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection", Hepatology, 71, pp.686~721 (2020)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)
- Chen-Hua Liu, "Sofosbuvir", velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis, 2021, pp.27(4), 575~588[DOI]
- Gane EJ, "Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3", 4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with hepatitis C virus genotype 1 or 3 infections, 2016, pp.151, 448~456
- Lawitz E, "Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial", Gastroenterology, 151, pp.893~901 (2016)
- Gane EJ, "Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2trial", Gastroenterology, 151, pp.902~909 (2016)
- Bourlière M, "Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection", N Engl J Med, 376, pp.2134~2146 (2017)
- Mak LY, "An update on the toxicological considerations for protease inhibitors used for hepatitis C infection", Expert Opin Drug Metab Toxicol, 14, pp.483~491 (2018)
- Mangia A, "Drug-drug interactions in italian patients with chronic hepatitis C treated with pangenotypic direct acting agents : insights from a real-world study", Int J Environ Res Public Health, 18, pp.7144~ (2021)
- Liu CH, "Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan", Aliment Pharmacol Ther, 48, pp.1290~1300 (2018)
- Desnoyer A, "Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C", J Hepatol, 65, pp.40~47 (2016)
- Borgia SM, "Sofosbuvir", velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis, 2019, pp.71, 660~665
- Liu CH, "Sofosbuvir", velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment, 2022, pp.71, 176~184
- De A, "Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy:a systematic review and meta-analysis", Nephrology(Carlton), 27, pp.82~89 (2022)
- 정정화, "Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study", Gut and Liver, 15(2), pp.295~306 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Feld JJ, "ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6infection", N Engl J Med, 373, pp.2599~2607 (2015)
- Foster GR, "Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection", N Engl J Med, 373, pp.2608~2617 (2015)
- Mangia A, "Global real-world evidence of sofosbuvir", velpatasvir as simple, effective HCV treatment : analysis of 5552 patients from 12 cohorts, 2020, pp.40, 1841~1852
- Liu CH, "Sofosbuvir", velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease : real-world data in Taiwan, 2021, pp.15, 338~349
- Degasperi E, "Real-life effectiveness and safety of sofosbuvir", velpatasvir, J Hepatol, pp.2019, 71[DOI]
- Belperio PS, "Real-world effectiveness of sofosbuvir", velpatasvir, J Viral Hepat, pp.2019, 26[DOI]
- Pearlman B, "Sofosbuvir", velpatasvir, pibrentasvir in chronic hepatitis C infection, pp.Am J Gastroenterol, 2019[DOI]
- Ruane P, "Sofosbuvir", velpatasvir, Velpatasvir-containing regimen : results from a retreatment study, pp.J Viral Hepat, 2019[DOI]
- Chen CY, "Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C : a real-world nationwide hepatitis C virus registry programme in Taiwan", Liver Int, 41, pp.1265~1277 (2021)
- Kwon JH, "Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens : a multicenter study in Korea", J Med Virol, 91, pp.1104~1111 (2019)
- Cheng PN, "Sofosbuvir", velpatasvir for hepatitis C Virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan, 2022, pp.11, 485~500